@article{36d6871a7b7242f4a800734477f8a4ed,
title = "Association of white matter microstructural integrity with cognition and dementia",
abstract = "Late-life measures of white matter (WM) microstructural integrity may predict cognitive status, cognitive decline, and incident mild cognitive impairment (MCI) or dementia. We considered participants of the Atherosclerosis Risk in Communities study who underwent cognitive assessment and neuroimaging in 2011–2013 and were followed through 2016–2017 (n = 1775 for analyses of prevalent MCI and dementia, baseline cognitive performance, and longitudinal cognitive change and n = 889 for analyses of incident MCI, dementia, or death). Cross-sectionally, both overall WM fractional anisotropy and overall WM mean diffusivity were strongly associated with baseline cognitive performance and risk of prevalent MCI or dementia. Longitudinally, greater overall WM mean diffusivity was associated with accelerated cognitive decline, as well as incident MCI, incident dementia, and mortality, but WM fractional anisotropy was not robustly associated with cognitive change or incident cognitive impairment. Both cross-sectional and longitudinal associations were attenuated after additionally adjusting for likely downstream pathologic changes. Increased WM mean diffusivity may provide an early indication of dementia pathogenesis.",
keywords = "Cognitive decline, Cognitive impairment, DTI, Dementia, MRI, White matter microstructural integrity",
author = "Power, {Melinda C.} and Dan Su and Aozhou Wu and Reid, {Robert I.} and Jack, {Clifford R.} and Knopman, {David S.} and Joe Coresh and Juebin Huang and Kejal Kantarci and Sharrett, {A. Richey} and Gottesman, {Rebecca G.} and Griswold, {Mike E.} and Mosley, {Thomas H.}",
note = "Funding Information: This work was supported by the United States National Institutes of Health (NIH) The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201700001I , HHSN268201700002I , HHSN268201700003I , HHSN268201700005I , HHSN268201700004I . Neurocognitive data is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NHLBI , National Institute of Neurological Disorders and Stroke (NINDS) , National Institute on Aging (NIA) and National Institute on Deafness and Other Communication Disorders (NIDCD) , and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI . The sponsors had no role in the study design; collection, analysis, or interpretation of the data; in the writing of the report; or in the decision to submit the article for publication. Funding Information: Drs Coresh, Griswold, Huang, Mosley, Power, Reid, Sharrett, and Wu, and Ms Su have nothing to declare. Dr Clifford R. Jack Jr consults for Lily and serves on an independent data monitoring board for Roche, but he received no personal compensation from any commercial entity. He received research support from the NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr David Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California; and received research support from the NIH . Kejal Kantarci serves on the Data Safety Monitoring Board for Takeda Global Research and Development Center, Inc; received research support from Avid Radiopharmaceuticals and Eli Lilly , and received funding from the NIH and Alzheimer's Drug Discovery Foundation . Dr Rebecca G. Gottesman is an associate editor for Neurology. Funding Information: Drs Coresh, Griswold, Huang, Mosley, Power, Reid, Sharrett, and Wu, and Ms Su have nothing to declare. Dr Clifford R. Jack Jr consults for Lily and serves on an independent data monitoring board for Roche, but he received no personal compensation from any commercial entity. He received research support from the NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr David Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California; and received research support from the NIH. Kejal Kantarci serves on the Data Safety Monitoring Board for Takeda Global Research and Development Center, Inc; received research support from Avid Radiopharmaceuticals and Eli Lilly, and received funding from the NIH and Alzheimer's Drug Discovery Foundation. Dr Rebecca G. Gottesman is an associate editor for Neurology.The authors thank the staff and participants of the ARIC study for their important contributions. This work was supported by the United States National Institutes of Health (NIH) The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I. Neurocognitive data is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NHLBI, National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA) and National Institute on Deafness and Other Communication Disorders (NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. The sponsors had no role in the study design; collection, analysis, or interpretation of the data; in the writing of the report; or in the decision to submit the article for publication.",
year = "2019",
month = nov,
doi = "10.1016/j.neurobiolaging.2019.08.021",
language = "English (US)",
volume = "83",
pages = "63--72",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
}